Yes, Vraylar (cariprazine) is an effective and FDA-approved medication for bipolar I disorder in adults.
Vraylar is FDA-approved for treating acute manic/mixed episodes and depressive episodes in bipolar I disorder, making it one of the few atypical antipsychotics with full-spectrum efficacy across both mood poles 1.
FDA-Approved Indications
Vraylar has three specific FDA approvals for bipolar I disorder:
- Acute manic or mixed episodes in adults and children ≥10 years
- Depressive episodes (bipolar depression) in adults
- Also approved for schizophrenia and as adjunctive treatment for major depressive disorder 1
This full-spectrum approval distinguishes Vraylar from most other atypical antipsychotics, which typically only have approval for one affective pole.
Evidence of Effectiveness
For Bipolar Depression
The most robust recent evidence comes from a 2019 phase 3 randomized controlled trial showing that both cariprazine 1.5 mg/day and 3.0 mg/day significantly reduced depressive symptoms compared to placebo, with least squares mean differences of -2.5 and -3.0 points on the MADRS scale respectively 2. The medication was generally well-tolerated with relatively small metabolic effects.
Real-world data from 2025 demonstrated clinically meaningful improvements in depression severity, with mean PHQ-9 reductions of 6.5-6.9 points at 6-12 months in bipolar I patients 3.
For Manic Episodes
Post hoc analyses from pooled randomized controlled trials demonstrated that cariprazine significantly reduced both manic and depressive symptoms in patients experiencing manic episodes, with low rates of treatment-emergent affective switch (TEAS) to the opposite pole 4.
Real-World Comparative Effectiveness
A 2026 real-world study comparing cariprazine to aripiprazole (another commonly used atypical antipsychotic) found that cariprazine was associated with 37% lower rates of manic events and 28% lower rates of depressive events, demonstrating superior real-world effectiveness 5.
Dosing Considerations
- For bipolar depression: Start at 1.5 mg/day; can increase to 3.0 mg/day based on response
- For acute mania/mixed episodes: Typically 3-12 mg/day range
- Take once daily, with or without food 1
Safety Profile
Common adverse effects (≥5% and twice placebo rate) include:
- Akathisia
- Nausea
- Headache
- Insomnia
- Sedation/drowsiness
- Weight gain (though metabolic changes are relatively small compared to some other atypicals) 1, 2
Critical safety warnings include increased mortality risk in elderly patients with dementia-related psychosis (black box warning) and increased suicidal thoughts/actions in patients <24 years old 1.
Clinical Advantages
Vraylar's unique pharmacology as a dopamine D3-preferring D3/D2 receptor partial agonist provides several benefits:
- Full-spectrum efficacy: Treats both manic and depressive poles without precipitating mood destabilization 4
- Low switch risk: Lower rates of treatment-emergent affective switch compared to placebo 4
- Anxiety benefits: Effective in bipolar depression patients with comorbid anxiety symptoms 6
- Favorable metabolic profile: Relatively small changes in weight and metabolic parameters compared to other atypical antipsychotics 2
Important Caveats
A 2024 maintenance study failed to demonstrate superiority over placebo in preventing mood episode relapses, though this was attributed to unusually low relapse rates in the placebo group 7. This suggests Vraylar's primary strength is in acute episode treatment rather than long-term maintenance monotherapy.
For maintenance therapy, consider combining Vraylar with traditional mood stabilizers (lithium, valproate) rather than using it as monotherapy, as the evidence base for maintenance is limited.